Key result
Sirolimus-eluting bioresorbable scaffold late lumen loss ≥0.5 mm linked to ~3-fold greater late absolute recoil.
Cohort (n=70)
Answers are grounded in this paper and cite their sources.
Background: The pathomechanisms underlying restenosis of the bioabsorbable sirolimus-eluting metallic scaffold (Magmaris) remain unknown. Using serial optical coherence tomography, we investigated causes of restenosis, including the contribution of late scaffold recoil versus neointimal hyperplasia. Methods: Patients enrolled in BIOSOLVE-II undergoing serial angiography and optical coherence tomography (post-intervention and follow-up: 6 months and/or 1 year) were analyzed. Patients were divided into 2 groups according to angiographic in-scaffold late lumen loss (LLL) <0.5 or ≥0.5 mm. End points were late absolute scaffold recoil and neointimal hyperplasia area as assessed by optical coherence tomography. Results: Serial data were available for analysis from 70 patients (LLL <0.5 mm: n=41; LLL ≥0.5 mm: n=29). Patient and lesion characteristics were comparable, and there was no significant difference in mean and minimal scaffold area between groups at post-intervention. Late absolute scaffold recoil was less among patients with LLL <0.5 mm (0.53±0.68 mm 2 ) compared with those with LLL ≥0.5 mm (1.48±1.20 mm 2 ; P <0.001). Neointimal hyperplasia area was smaller among patients with LLL <0.5 mm at follow-up (1.47±0.33 mm 2 ) compared with patients with LLL ≥0.5 mm (1.68±0.34 mm 2 ; P =0.013). In a matched-frame analysis (post-intervention and follow-up), late absolute scaffold recoil varied according to the underlying plaque type (lipid: 0.63±1.23 mm 2 ; calcified: 0.81±1.44 mm 2 ; and fibrous: 1.20±1.52 mm 2 ; P <0.001), while there was no difference with regards to neointimal hyperplasia area ( P =0.132). Conclusions: In addition to neointimal hyperplasia, late scaffold recoil contributed significantly to LLL of sirolimus-eluting absorbable metal scaffolds. The extent of late scaffold recoil was dependent on the underlying plaque morphology and was the highest among fibrotic lesions. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01960504.
No takes yet. Share an insight, caveat, or question.
Ueki et al. (2020) conducted a cohort in Restenosis of bioabsorbable sirolimus-eluting metallic scaffolds (n=70). Angiographic in-scaffold late lumen loss (LLL) ≥0.5 mm vs. Late lumen loss (LLL) <0.5 mm was evaluated on Late absolute scaffold recoil (p=<0.001). Sirolimus-eluting absorbable metal scaffolds with late lumen loss ≥0.5 mm showed greater late absolute recoil (1.48 vs 0.53 mm2; P<0.001) compared with LLL <0.5 mm.
Synapse has enriched 10 related papers. Consider them for comparative context: